Amylin sues Lilly over Boehringer deal; GSK agrees to disclose UNICEF prices;

@FiercePharma: Google near $500M settlement in pharmacy probe. News | Follow @FiercePharma

> Amylin Pharmaceuticals sued its longtime diabetes-drug partner Eli Lilly, saying the larger drugmaker breached their alliance by teaming up with Boehringer Ingelheim on a rival product. Report

> GlaxoSmithKline is now working with UNICEF to enable retrospective publication of the prices it charges the health program, as well as disclosure of future prices. Item

> Alexion Pharmaceutical is expanding its manufacturing plant in Rhode Island, a move expected to add 35 percent more jobs to its current employment of 125 there. News

> Biogen Idec said Australian regulators approved marketing of its multiple sclerosis drug Fampyra. Story

> AstraZeneca purchased for cancellation 334,454 ordinary shares at a price of 3199 pence per share. Article

> Merck South Africa, a subsidiary of Germany's Merck KGaA, has sold its manufacturing to a local private equity firm as part of its ongoing plan to streamline production at facilities around the world. Report

> South Africa's Aspen Pharmacare is working with the Johannesburg-area health department to resolve delays of several months of payments for its supply of AIDS drugs. Item

> U.K. Prime Minister David Cameron will say he is pressing ahead with an overhaul of the state-run National Health Service, rebutting political criticism and attacks from the medical profession. Article

> Dr. Reddy's Laboratories is looking to acquire medicine brands in Russia, CFO Umang Vohra said. Report

> The UK's pharma industry association the ABPI and its biotech equivalent the BIA are jointly relocating to new London offices. Report

> Investors in Alexion Pharmaceuticals approved a 2-for-1 stock split, taking the number of shares to 290 million. Story

Biotech News

 @FierceBiotech: iPierian fires top execs, shifts focus. News | Follow @FierceBiotech

 @JohnCFierce: Bloomberg's Langreth covers the growing number of cancer drugs in the pipeline which rely on epigenetics. Story Follow @JohnCFierce

> Analysis: Big Pharma is backing out of more biotech deals. Article 

> Novartis delivers promising Ph3 data for combo COPD treatment. Item 

> Sanofi forges $663M MS antibody development pact with Glenmark. Report 

> PacBio's Schadt leading $100M effort at Mt. Sinai. News 

> Metabolon plots fast growth as biomarker biz booms. Item 

Biotech IT News

> PerkinElmer acquires Labtronics, buyouts pile up. News 

> Scientists mount computer-aided attack on H1N1 flu virus. Report 

> Sequencing DNA is cheap, analysis not so much. Item

> My visit to Nimbus, Bill Gates' bet on virtual drug discovery. Article 

Medical Device News

> Neuronetics completes Series E, raises $30M. Story 

> Stryker to buy Orthovita for $304M. Report 

> Report: EU needs to do more to ensure device safety. Article 

> Varian Medical grabs $15M stake and buyout option from Augmenix. News 

> Harmac to create 100 jobs in Ireland. Item

> Sorensen named head of Siemens Healthcare in U.S., Canada. Article 

And Finally... Scientists have for the first time confirmed a specific genetic link to depression, according to new evidence published in the American Journal of Psychiatry. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.